Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMDZ

Immune Design (IMDZ) Stock Price, News & Analysis

Immune Design logo

About Immune Design Stock (NASDAQ:IMDZ)

Advanced Chart

Key Stats

Today's Range
$5.85
$5.85
50-Day Range
$5.85
$5.85
52-Week Range
$1.10
$5.85
Volume
N/A
Average Volume
374,216 shs
Market Capitalization
$282.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive IMDZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immune Design and its competitors with MarketBeat's FREE daily newsletter.

IMDZ Stock News Headlines

Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
See More Headlines

IMDZ Stock Analysis - Frequently Asked Questions

Immune Design Corp. (NASDAQ:IMDZ) announced its quarterly earnings data on Wednesday, August, 1st. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.01. The biotechnology company earned $0.76 million during the quarter, compared to analysts' expectations of $0.64 million. Immune Design had a negative trailing twelve-month return on equity of 49.56% and a negative net margin of 2,483.00%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immune Design investors own include Omeros (OMER), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Selecta Biosciences (SELB), TG Therapeutics (TGTX) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
8/01/2018
Today
7/10/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMDZ
CIK
1437786
Fax
N/A
Employees
48
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$54.76 million
Net Margins
-2,483.00%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.20 million
Price / Cash Flow
N/A
Book Value
$1.91 per share
Price / Book
3.06

Miscellaneous

Free Float
N/A
Market Cap
$282.96 million
Optionable
Optionable
Beta
3.48
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:IMDZ) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners